Praecis Pharmaceuticals, Inc.

Oncoceutics, Inc.

Provid Pharmaceuticals Inc.

Astrazeneca Ab

Rutgers, the State University of New Jersey

Supernus Pharmaceuticals, Inc.

Immune Control Inc.

University of California

University of Pennsylvania

Albert Einstein College of Medicine

Sequenom, Inc.

Palatin Technologies Incorporated

Corridor Pharmaceuticals, Inc.

Gary Olson

Christopher Self

Charles Michael Cook

Lily Lee

Jens Birktoft

Bhaskara Rao Nallaganchu

Richard S Pottorf

Martin Stogniew

Barry A Morgan

Joshua E Allen

Christopher C Arico-Muendel

Yanjun Sun

Bruce Edward Tomczuk

Richard Scott Pottorf

Lijuan Jane Wang

Richard H Ebright

Stephen A Roth

Yon W Ebright

Juan Shen

James Bacci

Anne-Cecile Hiebel

William Solvibile

Yanqun Zhang

Clayton Buck

Charles Cantor

Yi-Qun Shi

Mark A Findeis

Andreas Braun

Andrew Wasmuth

Kathryn Phillips

Axel Metzger

John H Dodd

David W Christianson

Victor L Schuster

Yuling Chi

Susan S Taylor

Andrew Vargha Colasanti

Stefan M Kammerer

Lora Burns-Hamuro

Elizabeth G Rowley

Bhaskara Nallaganchu

Andrew S Wasmuth

Provided are substituted derivatives of 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol having Formula (I): as well as their stereoisomers and their pharmaceutically acceptable salts. Such substituted derivatives may be used, for example, in pharmaceutical compositions for the treatment of central nervous system diseases or disorders. In addition, methods of making such substituted derivatives are also provided.

Substituted derivatives of isoindoles

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the following chemical structure:

Process of making derivatives of substituted morpholines

7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

Arginase inhibitors and methods of use

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy

The invention provides compounds of formula Ia, Ib and Ic: and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

Antibacterial agents: aryl myxopyronin derivatives

The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.

Arginase inhibitors and methods of use thereof

This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.

7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy

The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy

Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

Prostaglandin transporter inhibitors and uses thereof

The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

Inhibitors of antigen presentation by MHC class II molecules

Melanocortin receptor-specific compounds of formula I below: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders.

Melanocortin receptor-specific spiro-piperidine compounds

Growing community of inventors

Mountainside, NJ, United States of America

Gary Olson